Sarepta’s Elevidys is back on the market for ambulatory patients with Duchenne muscular dystrophy, Health Secretary Robert F. Kennedy Jr. reportedly plans to dissolve the U.S. Preventive Services Task ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Eisai and Biogen's Alzheimer's drug Leqembi continues to show promise in slowing disease progression, with no new safety issues observed over four years. The injectable form of Leqembi is under U.S.

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025.

Eli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton's ...

The scale of the Merck layoffs has not been revealed, but the company indicated that it would target roles in the ...

Dealmaking is in style again under President Donald Trump. Potential takeover targets include C3.ai, Viking Therapeutics, and ...

Steve Walsh, president and CEO of the Massachusetts Health and Hospital Association, has a deep understanding of ...